Studies on administration of thiamazole to breast-feeding mothers with Graves' disease

Setsuko Murase, Toru Sato, Hideya Kokubun, Toshimi Kimura, Masaaki Takahashi, Mitsuru Machida, Shigehiko Shimada, Takashi Nishikawa, Tsunehide Oyama, Mayumi Mochizuki, Yoshifumi Abe, Kunihiko Ito

Research output: Contribution to journalArticle

Abstract

We investigated the excretion of thiamazole, an antithyroid drug, in the milk of 6 mothers with Graves' disease. Thiamazole in serum or milk was determined by high performance liquid chromatography. The mothers had been taking thiamazole 5∼10 mg/day, before and after delivery. The drug concentration in serum was almost equal to that in milk; it reached maximum at about 2 hours after the previous administration and was considerably decreased at 12 hours. The babies were breast-fed at 12 hours or more after the previous administration, and the drug was not detected (below about 1 ng/ml) in the serum of any baby. Thyroid function test results were normal in all babies. These findings suggest that breast-feeding mothers with hyperthyroidism can continue thiamazole treatment, though further study is needed for assessment of safety, regarding the accumulation of the drug in the thyroid of babies.

Original languageEnglish
Pages (from-to)775-782
Number of pages8
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume30
Issue number6
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Methimazole
Graves Disease
Breast Feeding
Milk
Serum
Pharmaceutical Preparations
Thyroid Function Tests
Antithyroid Agents
Hyperthyroidism
Thyroid Gland
Breast
High Pressure Liquid Chromatography
Safety

Keywords

  • Antithyroid drug
  • Breast milk
  • Lactation
  • Mothers with Graves' disease
  • Pharmacokinetics of thiamazole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Murase, S., Sato, T., Kokubun, H., Kimura, T., Takahashi, M., Machida, M., ... Ito, K. (1999). Studies on administration of thiamazole to breast-feeding mothers with Graves' disease. Japanese Journal of Clinical Pharmacology and Therapeutics, 30(6), 775-782.

Studies on administration of thiamazole to breast-feeding mothers with Graves' disease. / Murase, Setsuko; Sato, Toru; Kokubun, Hideya; Kimura, Toshimi; Takahashi, Masaaki; Machida, Mitsuru; Shimada, Shigehiko; Nishikawa, Takashi; Oyama, Tsunehide; Mochizuki, Mayumi; Abe, Yoshifumi; Ito, Kunihiko.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 30, No. 6, 1999, p. 775-782.

Research output: Contribution to journalArticle

Murase, S, Sato, T, Kokubun, H, Kimura, T, Takahashi, M, Machida, M, Shimada, S, Nishikawa, T, Oyama, T, Mochizuki, M, Abe, Y & Ito, K 1999, 'Studies on administration of thiamazole to breast-feeding mothers with Graves' disease', Japanese Journal of Clinical Pharmacology and Therapeutics, vol. 30, no. 6, pp. 775-782.
Murase, Setsuko ; Sato, Toru ; Kokubun, Hideya ; Kimura, Toshimi ; Takahashi, Masaaki ; Machida, Mitsuru ; Shimada, Shigehiko ; Nishikawa, Takashi ; Oyama, Tsunehide ; Mochizuki, Mayumi ; Abe, Yoshifumi ; Ito, Kunihiko. / Studies on administration of thiamazole to breast-feeding mothers with Graves' disease. In: Japanese Journal of Clinical Pharmacology and Therapeutics. 1999 ; Vol. 30, No. 6. pp. 775-782.
@article{126c22473028437c822aad5059d4cf14,
title = "Studies on administration of thiamazole to breast-feeding mothers with Graves' disease",
abstract = "We investigated the excretion of thiamazole, an antithyroid drug, in the milk of 6 mothers with Graves' disease. Thiamazole in serum or milk was determined by high performance liquid chromatography. The mothers had been taking thiamazole 5∼10 mg/day, before and after delivery. The drug concentration in serum was almost equal to that in milk; it reached maximum at about 2 hours after the previous administration and was considerably decreased at 12 hours. The babies were breast-fed at 12 hours or more after the previous administration, and the drug was not detected (below about 1 ng/ml) in the serum of any baby. Thyroid function test results were normal in all babies. These findings suggest that breast-feeding mothers with hyperthyroidism can continue thiamazole treatment, though further study is needed for assessment of safety, regarding the accumulation of the drug in the thyroid of babies.",
keywords = "Antithyroid drug, Breast milk, Lactation, Mothers with Graves' disease, Pharmacokinetics of thiamazole",
author = "Setsuko Murase and Toru Sato and Hideya Kokubun and Toshimi Kimura and Masaaki Takahashi and Mitsuru Machida and Shigehiko Shimada and Takashi Nishikawa and Tsunehide Oyama and Mayumi Mochizuki and Yoshifumi Abe and Kunihiko Ito",
year = "1999",
language = "English",
volume = "30",
pages = "775--782",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "6",

}

TY - JOUR

T1 - Studies on administration of thiamazole to breast-feeding mothers with Graves' disease

AU - Murase, Setsuko

AU - Sato, Toru

AU - Kokubun, Hideya

AU - Kimura, Toshimi

AU - Takahashi, Masaaki

AU - Machida, Mitsuru

AU - Shimada, Shigehiko

AU - Nishikawa, Takashi

AU - Oyama, Tsunehide

AU - Mochizuki, Mayumi

AU - Abe, Yoshifumi

AU - Ito, Kunihiko

PY - 1999

Y1 - 1999

N2 - We investigated the excretion of thiamazole, an antithyroid drug, in the milk of 6 mothers with Graves' disease. Thiamazole in serum or milk was determined by high performance liquid chromatography. The mothers had been taking thiamazole 5∼10 mg/day, before and after delivery. The drug concentration in serum was almost equal to that in milk; it reached maximum at about 2 hours after the previous administration and was considerably decreased at 12 hours. The babies were breast-fed at 12 hours or more after the previous administration, and the drug was not detected (below about 1 ng/ml) in the serum of any baby. Thyroid function test results were normal in all babies. These findings suggest that breast-feeding mothers with hyperthyroidism can continue thiamazole treatment, though further study is needed for assessment of safety, regarding the accumulation of the drug in the thyroid of babies.

AB - We investigated the excretion of thiamazole, an antithyroid drug, in the milk of 6 mothers with Graves' disease. Thiamazole in serum or milk was determined by high performance liquid chromatography. The mothers had been taking thiamazole 5∼10 mg/day, before and after delivery. The drug concentration in serum was almost equal to that in milk; it reached maximum at about 2 hours after the previous administration and was considerably decreased at 12 hours. The babies were breast-fed at 12 hours or more after the previous administration, and the drug was not detected (below about 1 ng/ml) in the serum of any baby. Thyroid function test results were normal in all babies. These findings suggest that breast-feeding mothers with hyperthyroidism can continue thiamazole treatment, though further study is needed for assessment of safety, regarding the accumulation of the drug in the thyroid of babies.

KW - Antithyroid drug

KW - Breast milk

KW - Lactation

KW - Mothers with Graves' disease

KW - Pharmacokinetics of thiamazole

UR - http://www.scopus.com/inward/record.url?scp=0041820036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041820036&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0041820036

VL - 30

SP - 775

EP - 782

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 6

ER -